| Callisto Pharmaceuticals develops drugs for the treatment of cancer. Its two primary drug candidates are Annamycin, which treats relapsed leukemia, and Atiprimod, a treatment for bone resorption and multiple myeloma (blood cancer). The company has licensing agreements with AnorMED and M.D. Anderson Cancer Center. It also acquired the rights to Site Directed Intercalation (SDI) from Houston Pharmaceuticals. The technology is used to identify potential drug candidates. In addition to its work in cancer treatment, Callisto is collaborating with Rockefeller University to develop defenses against biological weapons.
biz.yahoo.com
==========================================
Callisto Pharmaceuticals Announces Poster Presentation on Atiprimod at Major Scientific Meeting in December
Thursday December 1, 4:01 pm ET
Research on Atiprimod's Effect on Leukemia Cells to Be Presented at American Society of Hematology Annual Meeting
biz.yahoo.com
==========================================
British Journal of Cancer (2005) 93, 70-80.
doi:10.1038/sj.bjc.6602637 Published online 21 June 2005
Atiprimod blocks STAT3 phosphorylation and induces apoptosis in multiple myeloma cells
M Amit-Vazina1, S Shishodia1, D Harris1, Q Van1, M Wang2, D Weber2, R Alexanian2, M Talpaz1, B B Aggarwal1 and Z Estrov1
1Department of Bioimmunotherapy, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
2Department Lymphoma/Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
Correspondence to: Dr Z Estrov, Department of Leukemia, Unit 428, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA. E-mail: zestrov@mdanderson.org
Revised 8 April 2005; accepted 2 May 2005; published online 21 June 2005
Multiple myeloma (MM) accounts for 1 % of all cancer deaths. Although treated aggressively, almost all myelomas eventually recur and become resistant to treatment. Atiprimod (2-(3-Diethylaminopropyl)-8,8-dipropyl-2-azaspiro[4,5] decane dimaleate) has exerted anti-inflammatory activities and inhibited oeteoclast-induced bone resorption in animal models and been well tolerated in patients with rheumatoid arthritis in phase I clinical trials. Therefore, we investigated its activity in MM cells and its mechanism of action. We found that Atiprimod inhibited proliferation of the myeloma cell lines U266-B1, OCI-MY5, MM-1, and MM-1R in a time- and dose-dependent manner. Atiprimod blocked U266-B1 myeloma cells in the G0/G1 phase, preventing cell cycle progression. Furthermore, Atiprimod inhibited signal transducer and activator of transcription (STAT) 3 activation, blocking the signalling pathway of interleukin-6, which contributes to myeloma cell proliferation and survival, and downregulated the antiapoptotic proteins Bcl-2, Bcl-XL, and Mcl-1. Incubation of U266-B1 myeloma cells with Atiprimod induced apoptosis through the activation of caspase 3 and subsequent cleavage of the DNA repair enzyme poly(adenosine diphosphate-ribose) polymerase. Finally, Atiprimod suppressed myeloma colony-forming cell proliferation in fresh marrow cells from five patients with newly diagnosed MM in a dose-dependent fashion. These data suggest that Atiprimod has a role in future therapies for MM.
Keywords: multiple myeloma; signal transduction; clonogenic assay; nuclear factor B, apoptosis
nature.com
==========================================
EquityNet Research Initiates Coverage of Callisto Pharmaceuticals with Buy Rating and Projected 12-Month Share Price of $3.45
Friday December 2, 4:01 pm ET
Report Cites Key Strategic Research Partnerships and Demand for New Anti-Cancer Drugs and Novel Treatments
equitynet.net
==========================================
clinicaltrials.gov
========================================== |
|
